Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + anti-EGFR (GEMCAD LIVERPEARL regimen)
- Development stage
- Unknown
- Lead developer
- Grupo Cooperativo GEMCAD
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
bevacizumab + anti-EGFR (GEMCAD LIVERPEARL regimen) refers to the stratified monoclonal antibody therapy used in the LIVERPEARL-I clinical trial (NCT03088332) sponsored by the Grupo Español Multidisciplinario del Cancer Digestivo (GEMCAD). This treatment strategy involves the administration of either bevacizumab (an anti-VEGF antibody) or an anti-EGFR antibody (such as cetuximab or panitumumab) in combination with modified FOLFOX6 (FOLFOX6m) chemotherapy. The choice of antibody is determined by the patient's RAS mutational status: RAS-mutated patients receive bevacizumab, while RAS wild-type patients receive an anti-EGFR agent. This regimen is used as the systemic backbone to treat patients with colorectal cancer and liver-limited metastases, often compared against the addition of irinotecan-loaded microsphere chemoembolization.
- Other names
- FOLFOX6m + mAb (GEMCAD)bevacizumab or anti-EGFR with FOLFOX6m
02
Targets
Beyond the preview
Go deeper on bevacizumab + anti-EGFR (GEMCAD LIVERPEARL regimen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + anti-EGFR (GEMCAD LIVERPEARL regimen).